SMMT: financial statements from SEC — TradeAlmanac

SMMT

Summit Therapeutics Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Sep 30, 2024	Jun 30, 2024
Revenue	—	—	—	—	0	—
Research and development	133m	—	—	51m	—	—
Selling, general and administrative	63m	103m	360m	16m	21m	14m
Operating expenses	195m	234m	568m	67m	58m	60m
Operating income	—	—	—	—	−58m	−60m
Net income	−189m	−232m	−566m	−63m	−56m	−60m
Earnings per share	−0.24	−0.31	−0.76	−0.09	−0.08	−0.09
Earnings per share, diluted	−0.24	−0.31	−0.76	−0.09	−0.08	−0.09
Weighted average shares	775m	743m	743m	738m	727m	708m
Weighted average shares, diluted	775m	743m	743m	738m	727m	708m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	107m	225m	239m	298m	212m	105m	94m	28m
Short-term investments	492m	488m

Cash flow

Metric	Mar 31, 2026	Mar 31, 2025
Operating cash flow	−122m	−61m
Depreciation and amortisation	44,000	25,000
Share-based compensation	73m	11m
Capital expenditure	245,000	422,000
Investing cash flow	−238,000	160m
Financing cash flow	4m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)